Literature DB >> 27049022

Urologic cancer in China.

Cheng Pang1, Youyan Guan2, Hongbo Li3, Wanqing Chen4, Gang Zhu5.   

Abstract

Cancer remains to be the second most common cause of death, and its incidence and mortality rates are increasing in China. According to the 2015 National Central Cancer Registry (NCCR) of China, the incidence of bladder cancer and prostate cancer ranked sixth and seventh, respectively, in male cancers. The majority of prostate cancer patients were diagnosed at an advanced stage. Early diagnosis of prostate cancer is the key to improve prostate cancer survival in China. Radical prostatectomy or radical radiotherapy is the main treatment for localized prostate cancer, and a comprehensive therapy based on androgen deprivation therapy is the treatment for advanced disease. The most common histologic types of bladder cancer in China were urothelial carcinoma, followed by adenocarcinoma and squamous carcinoma. The majority of patients were diagnosed using white-light cystoscopy with biopsy. Fluorescence and narrow-band imaging cystoscopy had additional detection rates and are becoming more popular. Following Chinese guidelines, most non-muscle invasive bladder cancer patients were treated with diagnostic transurethral resection and more than half of the muscle invasive bladder cancer patients were treated with radical cystectomy. Due to the increased detection rate of kidney tumors by ultrasound in physical examination, the number of incidentally diagnosed renal cell carcinoma has increased. Localized kidney cancers are more and more often treated by nephron-sparing surgery. Radical nephrectomy is still the main treatment option for patients with locally advanced renal cell carcinoma. Both laparoscopic and robotic-assisted laparoscopic surgeries have been used in big medical centers. Both testicular cancer and penile cancer have lower incidence levels than that in Europe. As we have an enormous population base, the absolute patient number is big. The diagnosis and treatment follows the Chinese guidelines. In China, both medical professionals and public should concern more on the early diagnosis, as there is not enough cancer prevention information available. Urologists should also take a more active role in educating the population.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bladder cancer; diagnosis; kidney cancer; prostrate cancer; treatment

Mesh:

Year:  2016        PMID: 27049022     DOI: 10.1093/jjco/hyw034

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  51 in total

1.  Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis.

Authors:  Chen Fang; Le Xu; Wei He; Jun Dai; Fukang Sun
Journal:  Cell Cycle       Date:  2019-10-15       Impact factor: 4.534

2.  [Propensity-matched comparison of laparoscopic and open radical cystectomy for female patients with bladder cancer].

Authors:  H W Huang; B Yan; M X Shang; L B Liu; H Hao; Z J Xi
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

3.  Genetic Variations in the 3'-untranslated Regions of Genes Involved in the Cell Cycle and Apoptosis Pathways Affect Bladder Cancer Risk.

Authors:  Qiang Zhang; Wenying Wang; Weidong Xu; Mulong Du`; Gaoxiang Ma; Hanting Liu; Haiyan Chu; N A Tong; Meilin Wang; Jianfeng Shao; Zhengdong Zhang; Lin Yuan; Jing Qian
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

4.  Prevalence of human papillomavirus and implication on survival in Chinese penile cancer.

Authors:  Chengbiao Chu; Keming Chen; Xingliang Tan; Jiangli Lu; Yuanzhong Yang; YiJun Zhang; Kai Yao; Yun Cao
Journal:  Virchows Arch       Date:  2020-05-19       Impact factor: 4.064

5.  Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway.

Authors:  Zhong-Ming Huang; Hai Wang; Zhi-Gang Ji
Journal:  Inflamm Res       Date:  2021-08-14       Impact factor: 4.575

6.  microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Authors:  Guanlin Wu; Jian Wang; Guojun Chen; Xing Zhao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Effect of ERβ-regulated ERK1/2 signaling on biological behaviors of prostate cancer cells.

Authors:  Zhankui Zhao; Honglian Yu; Qingsheng Kong; Chuanxin Liu; Yanjun Tian; Xiaoli Zeng; Dandan Li
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

8.  Circular RNA UBAP2 promotes the proliferation of prostate cancer cells via the miR-1244/MAP3K2 axis.

Authors:  Xiaodong Li; Baihetiya Azhati; Wenguang Wang; Mulati Rexiati; Chen Xing; Yujie Wang
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

9.  Identifying Critical States of Complex Diseases by Single-Sample Jensen-Shannon Divergence.

Authors:  Jinling Yan; Peiluan Li; Rong Gao; Ying Li; Luonan Chen
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  High-throughput sequencing identified circular RNA circUBE2K mediating RhoA associated bladder cancer phenotype via regulation of miR-516b-5p/ARHGAP5 axis.

Authors:  Chen Yang; Zezhong Mou; Siqi Wu; Yuxi Ou; Zheyu Zhang; Xinan Chen; Xiyu Dai; Chenyang Xu; Shanhua Mao; Haowen Jiang
Journal:  Cell Death Dis       Date:  2021-07-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.